Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - ascorbic acid 200 mg in 10 ml - infuvite adult is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite adult is contraindicated in patients who have infuvite adult has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for their condition, because their vitamin requirements may exceed those of nonpregnant women. animal reproduction studies have not been conducted with infuvite adult. infuvite adult has not been studied in lactating women.lactating women should follow the u.s. recommended daily allowances for their condition, because their vitamin requirement may exceed those of nonlactating women. caution should be exercised when infuvite adult is administered to a nursing mother. safety and effectiveness in children below the age of 11 years have not been establish

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - zinc; ascorbic acid; biotin; cyanocobalamin; folic acid; nicotinamide; pantothenic acid; pyridoxine; riboflavin; calcium; chromium; copper; iodine; iron; ergocalciferol; tocopheryl acetate; selenium; vitamin a; thiamine; magnesium; manganese; molybdenum; potassium; phosphorus - oral capsule - 15mg ; 60mg ; 100microgram ; 3microgram ; 400microgram ; 18mg ; 4mg ; 2mg ; 1.6mg ; 100mg ; 200microgram ; 2mg ; 140microgram ; 12mg ; 400unit ; 10mg ; 50microgram ; 2500unit ; 1.2mg ; 30mg ; 3mg ; 250microgram ; 4mg ; 77mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - nicotinamide; pyridoxine hydrochloride; riboflavin; thiamine hydrochloride - oral tablet - 20mg ; 2mg ; 2mg ; 5mg

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - calcium ascorbate,calcium pantothenate,cyanocobalamin,nicotinamide,pyridoxine hydrochloride,riboflavin,riboflavine,thiamine nitrate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 100 mg/ml; riboflavine sodium phosphate, quantity: 2 mg/ml; nicotinamide, quantity: 20 mg/ml; dexpanthenol, quantity: 20 mg/ml; pyridoxine hydrochloride, quantity: 40 mg/ml; cyanocobalamin, quantity: 0.4 mg/ml - injection, solution - excipient ingredients: disodium edetate; benzyl alcohol; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7. carpal tunnel syndrome. 8. pernicious anaemia as a result of in situ b12 deficiency. general indications include: 1. angular stomatitis and glossitis have been shown in some instances to respond to t

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

br pharmaceuticals ltd - nicotinamide; riboflavin; thiamine hydrochloride - oral tablet - 15mg ; 1mg ; 1mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalkeith laboratories ltd - nicotinamide; riboflavin; thiamine hydrochloride - oral tablet - 15mg ; 1mg ; 1mg

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - nicotinamide; riboflavin; thiamine hydrochloride - oral tablet - 15mg ; 1mg ; 1mg